Overcoming Challenges in the Management of Psoriasis: Treatment Advances to Improve Standard of Care

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from February 1, 2019 to February 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals Corporation

Description:
Psoriasis is a complex, chronic, immune-mediated inflammatory disease that affects approximately 7 million, or just over 2%, of the population in the United States. Psoriasis is a periodic flare-up of sharply defined red patches, covered by a silvery, flaky surface. The main disease activity leading to psoriasis occurs in the epidermis, the top five layers of the skin. Psoriasis is a complex disease to manage, but the goal should be a patient-centered treatment that reduces disease burden, improves on quality-of-life, and addresses the risks of systemic complications and comorbid conditions.

There are several treatment options. Topical treatments, from over the counter (OTC) to prescription are usually the first line treatment. Phototherapy may be tried, using controlled times of a special light or sunlight. To treat a chronic localized area, laser therapy may be used. However, should these therapies prove unsuccessful, especially in moderate to severe psoriasis, other treatments may be utilized. These treatments include traditional systemic medication, which may be prescribed orally or by injection, newer oral medications which are targeted small molecule medications, and biologics, which are derived from living cells that have been cultivated in a laboratory. Recent research indicates that both IL-23 and IL-17 play important, and perhaps integral, roles in the development of psoriatic plaques. Treatments such as guselkumab and tildrakizumab targeting IL-23 and brodalumab, ixekizumab, and secukinumab targeting IL-7 have shown safety and good efficacy in clinical trials of moderate-to-severe plaque psoriasis, but long-term safety still needs to be established.

Upon completion of this activity, participants will be able to:

  • Analyze the clinical data regarding the safety and efficacy of systemic biologic treatment options for psoriasis

  • Discuss the most up-to-date diagnostic criteria for moderate to severe psoriasis

  • Evaluate the challenges of treatment for patients with comorbidities and complications

  • Assess the mechanisms of action for biological therapies with IL-17 and IL-23 pathway inhibitors in patients with moderate to severe psoriasis

  • Examine the advances in psoriasis pathogenesis that inform the development of appropriate individualized treatment plans
     

Faculty: Robert E. Kalb, MD
Clinical Professor Department of Dermatology
State University of New York (SUNY) at Buffalo
School of Medicine and Biomedical Sciences

Disclosure:

Dr. Kalb serves on an advisory board for Dermatology Safety Monitoring Board and Eli Lilly. He serves as a consultant for Dermira, Janssen and Novartis. He has received grant/research support from AbbVie, Amgen, Janssen, Merck, and Novartis. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Novartis Pharmaceuticals Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue